Pituitary Adenylate Cyclase-Activating Polypeptide Prevents Cisplatin-Induced Renal Failure

@article{Li2010PituitaryAC,
  title={Pituitary Adenylate Cyclase-Activating Polypeptide Prevents Cisplatin-Induced Renal Failure},
  author={Min Li and Saravanan Balamuthusamy and Altaf M. Khan and Jerome L. Maderdrut and Eric E. Simon and Vecihi Batuman},
  journal={Journal of Molecular Neuroscience},
  year={2010},
  volume={43},
  pages={58-66}
}
Cisplatin is widely used for cancer chemotherapy, but nephrotoxicity is a major dose-limiting side effect. Our recent studies in vitro have shown that pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorated cisplatin nephrotoxicity and that the renoprotection with PACAP38 was mediated by the PAC1 receptor and through the p53-dependent and -independent suppression of apoptosis of human renal proximal tubular epithelial cells. In the present studies, PACAP38 prevented the rise in… CONTINUE READING